Vivos Inc (RDGL)

[AMB67]

Yes. Exactly. First and foremost, I believe that the stock is worth $30-60 pre-revenue...PRE-revenue based on Dr. Korenko and his team's thorough research, feedback from the medical community and plans for testing, some of which are currently being executed. I was estimating $1.50 - $5 under the previous leadership. 18 indications not including pediatric cancer indications and pet cancer indications?! Come on! $40 million in revenue for the vet side of the house after 1% penetration into the market alone is crazy. Generating revenue from all indications (including pediatric and vet) domestically and internationally would be absurd (in a positive way). Now, I believe that this mornings press release is extremely positive news!! However, the looming RS could put a damper on things. I HOPE that they do the RS after contracts are signed if it is even needed at that point. The ROI at these levels, once the potential of the company is realized by the market, should make good on the CEOs statement to create shareholder value. This company and in turn its loyal shareholders has been put through the wringer due to several years of mismanagement.